Free Trial

Generation Bio (GBIO) Competitors

Generation Bio logo
$6.18 -0.10 (-1.52%)
As of 01:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GBIO vs. ELDN, ACTU, CCCC, GNLX, THTX, CTOR, ZURA, TVGN, MOLN, and NVCT

Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Eledon Pharmaceuticals (ELDN), Actuate Therapeutics (ACTU), C4 Therapeutics (CCCC), Genelux (GNLX), Theratechnologies (THTX), Citius Oncology (CTOR), Zura Bio (ZURA), Tevogen Bio (TVGN), Molecular Partners (MOLN), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry.

Generation Bio vs. Its Competitors

Generation Bio (NASDAQ:GBIO) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

95.2% of Generation Bio shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 21.8% of Generation Bio shares are held by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Generation Bio presently has a consensus price target of $10.67, suggesting a potential upside of 72.74%. Eledon Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 266.97%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Generation Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Generation Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Eledon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Generation Bio. MarketBeat recorded 1 mentions for Eledon Pharmaceuticals and 0 mentions for Generation Bio. Eledon Pharmaceuticals' average media sentiment score of 1.02 beat Generation Bio's score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Generation Bio Neutral
Eledon Pharmaceuticals Positive

Eledon Pharmaceuticals has a net margin of 0.00% compared to Generation Bio's net margin of -341.12%. Generation Bio's return on equity of -91.07% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Generation Bio-341.12% -91.07% -33.65%
Eledon Pharmaceuticals N/A -92.51%-38.31%

Eledon Pharmaceuticals has lower revenue, but higher earnings than Generation Bio. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Generation Bio$21.23M1.96-$131.67M-$10.82-0.57
Eledon PharmaceuticalsN/AN/A-$36.18M-$1.17-2.33

Generation Bio has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Summary

Eledon Pharmaceuticals beats Generation Bio on 8 of the 15 factors compared between the two stocks.

Get Generation Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GBIO vs. The Competition

MetricGeneration BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$41.58M$3.31B$6.12B$10.53B
Dividend YieldN/A2.29%5.51%4.67%
P/E Ratio-0.5721.5685.7226.88
Price / Sales1.96412.90581.25184.02
Price / CashN/A46.3226.3031.10
Price / Book0.4810.0213.226.67
Net Income-$131.67M-$52.22M$3.30B$276.44M
7 Day Performance0.90%5.57%4.78%3.10%
1 Month Performance3.09%11.80%8.42%10.19%
1 Year Performance-73.27%25.31%87.67%40.32%

Generation Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GBIO
Generation Bio
3.631 of 5 stars
$6.18
-1.5%
$10.67
+72.7%
-74.7%$41.58M$21.23M-0.57150
ELDN
Eledon Pharmaceuticals
2.3753 of 5 stars
$2.54
-5.6%
$10.00
+293.7%
+9.2%$161.08MN/A-2.1710Positive News
Gap Up
ACTU
Actuate Therapeutics
1.4841 of 5 stars
$6.77
-1.7%
$20.33
+200.3%
-5.9%$160.15MN/A0.0010
CCCC
C4 Therapeutics
3.7147 of 5 stars
$2.23
flat
$8.50
+281.2%
-57.6%$158.71M$35.58M-1.41150
GNLX
Genelux
1.4777 of 5 stars
$4.25
+1.2%
$20.33
+378.4%
+80.2%$158.65MN/A-4.9410Positive News
THTX
Theratechnologies
N/A$3.42
+0.9%
N/A+184.3%$157.21M$84.38M-17.99140Upcoming Earnings
High Trading Volume
CTOR
Citius Oncology
3.3424 of 5 stars
$2.03
+1.5%
$6.00
+195.6%
+57.1%$156.74MN/A0.00N/AGap Up
ZURA
Zura Bio
3.1591 of 5 stars
$2.99
+24.1%
$11.60
+288.0%
-4.8%$156.69MN/A-4.273High Trading Volume
TVGN
Tevogen Bio
2.3586 of 5 stars
$0.79
-1.1%
$10.00
+1,169.7%
+132.5%$156.64MN/A-4.153
MOLN
Molecular Partners
1.1005 of 5 stars
$3.74
-2.9%
$8.00
+113.9%
-25.9%$155.32M$681K-1.80180Positive News
NVCT
Nuvectis Pharma
2.6741 of 5 stars
$5.92
-2.6%
$15.33
+159.0%
-0.8%$154.78MN/A-5.068

Related Companies and Tools


This page (NASDAQ:GBIO) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners